AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
Preliminary preclinical data supporting NiloT-PCL-Lf-NPs as a viable targeted nanotherapeutic platform for colorectal cancer is provided, warranting additional in vivo validation.
The developed chitosan-coated Eudragit® S100 nanoparticle system represents a promising platform for sustained, colon-targeted oral delivery of HSP and other poorly bioavailable bioactive compounds.
Andrographolide (AG) has been reported for its anticancer activity. However, it is classified as a class IV in the biopharmaceutics classification system (BCS). Therefore, AG possesses low bioavailability due to its low solubility and permeability. In this study, hyaluronic acid-coated chitosan nanoparticles (Hyalo-CS-...
The developed nanoliposomal system offers significant clinical advantages including potential for enhanced tumor targeting, reduced dosing frequency, and minimized systemic toxicity, pending in vivo validation, and improved therapeutic outcomes.
A magnetically responsive, biocompatible Fe3O4@SiO2 nanoparticle functionalized with a bromocholine-based ionic liquid that combines tunable drug release, biointerfacial compatibility, and rapid healing efficacy, making it a promising candidate for advanced wound therapy.
This study explored the potential of gold nanorods (AuNRs) functionalized with polyethylene glycol (PEG) and loaded with non-steroidal anti-inflammatory drugs (NSAIDs) fenamic acid (fenH) or its bromo-derivative (4′BrfenH) for targeted drug delivery and preclinical cancer research, given their pH-dependent drug-release...
Improved Cabozantinib delivery via Cabozantinib-loaded poly(lactic-co-glycolic acid) nanoparticles, prepared by solvent evaporation represents improved Cabozantinib delivery via Cabozantinib-loaded poly(lactic-co-glycolic acid) nanoparticles that overcomes pharmacokinetic pitfalls of CBZT.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.